个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Li Y[1,2] ; Zeng H[1,2] ; Qi C[1,2] ; Tan S[1,2] ; Huang Q[1,2] ; Pu X[1,2] ; Li W[1] ; Planchard D[3,4] ; Tian P[1,2] ;
机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, People’s Republic of China [3]Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif [4]The Faculty of Medicine, Paris-Saclay University, Paris, France
出处：
DOI： 10.1016/j.esmoop.2024.103935

关键词： non-small-cell lung cancer EGFR mutations BRAF alterations resistance to EGFR-TKIs

摘要：
The recommended first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients is EGFR-tyrosine kinase inhibitors (EGFR-TKIs). BRAF alterations have been identified as resistance mechanisms. We aimed to identify features of and subsequent treatment strategies for such patients.We conducted a systematic literature review of NSCLC patients harboring acquired BRAF alterations. Additionally, BRAF-altered NSCLC patients who progressed from EGFR-TKIs at West China Hospital of Sichuan University were screened. Patient characteristics, treatment options, and outcomes were analyzed.A total of 104 patients were included, 2 of whom came from our center. Seventy-five patients (72.1%) harbored BRAF mutations (57 class I mutations, 7 class II mutations, 9 class III mutations, and 2 non-class I-III mutations), and 29 (27.9%) harbored BRAF fusions. Eighteen patients received triple-targeted therapy, including prior EGFR-TKIs plus dabrafenib and trametinib, and 23 patients received other treatments. The median progression-free survival was significantly longer in patients receiving triple-targeted therapy than in those receiving other treatments (8.0 versus 2.5 months, P < 0.001). Similar findings were observed in patients with BRAF mutations (9.0 versus 2.8 months, P = 0.004), particularly in those with BRAF class I mutations (9.0 versus 2.5 months, P < 0.001). A potential benefit was also observed among patients with BRAF fusions (5.0 versus 2.0 months, P = 0.230). Twenty patients (48.8%) experienced adverse events. Dose reduction of RAF or MEK inhibitor was required in five patients (12.2%). Five patients (12.2%) permanently discontinued treatment (three on triple-targeted therapy; one on prior EGFR-TKI plus vemurafenib; one on prior EGFR-TKI plus trametinib).BRAF alterations, specifically BRAF mutations and BRAF fusions, facilitate resistance to EGFR-TKIs. Triple-targeted therapy is effective and safe for patients with EGFR-mutant NSCLC with acquired BRAF alterations, mainly among patients with BRAF class I mutations and potentially in patients with BRAF fusions.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

基金：
National Natural Science Foundation of China [grant numbers 82072598 to P Tian, 92159302 to W Li]; Science and Technology Project of Sichuan, China [grant number 2022ZDZX0018 to W Li]; and 1-3-5 project for disciplines of excellence, West China Hospital, Sichuan University, China [grant numbers ZYJC21052 to P Tian, ZYGD22009 to W Li].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, People’s Republic of China [3]Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif [4]The Faculty of Medicine, Paris-Saclay University, Paris, France
推荐引用方式(GB/T 7714)：
Li Y,Zeng H,Qi C,et al.Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors[J].ESMO Open.2024,9(10):103935.doi:10.1016/j.esmoop.2024.103935.
APA：
Li Y,Zeng H,Qi C,Tan S,Huang Q...&Tian P.(2024).Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.ESMO Open,9,(10)
MLA：
Li Y,et al."Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors".ESMO Open 9..10(2024):103935

相关文献

[1]The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. [2]EGFR突变型晚期非小细胞肺癌患者预后因素分析 [3]Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes [4]A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations [5]Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18 [6]Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations. [7]A PROSPECTIVE, MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH ADENOCARCINOMA HISTOLOGY (PIONEER STUDY) - CHINA SUBSET ANALYSIS [8]TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations [9]Pleural effusion as a substitute for tumor tissue in detecting EGFR/ALK mutations in non-small cell lung cancer: A systematic review and meta-analysis. [10]Development and validation of novel radiomics-based nomograms for the prediction of EGFR mutations and Ki-67 proliferation index in non-small cell lung cancer.

资源点击量：46666 今日访问量：3 总访问量：3332 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号